Further Development of an Anti-EGFR Bispecific Antibody for Metastatic Colorectal Cancer and a Platform Asset
Lead Participant:
SHYDEN BIOTECHNOLOGY LTD
Abstract
ShyDen Biotechnology is a start-up antibody drug discovery company based in the Open
Innovation incubator, The Stevenage Bioscience Catalyst. It is discovering and developing the
next generation of bispecific antibodies that can be switched on or off, thus carrying a new
level of molecular regulation and thus safety. This project is to extend our work and build on
the success from a previous SMART award to further develop our prototype as well as derive
a more valuable platform technology to discover further product candidates. This will be
aimed at metastatic colorectal cancer, but later other solid cancers could be targeted.
Innovation incubator, The Stevenage Bioscience Catalyst. It is discovering and developing the
next generation of bispecific antibodies that can be switched on or off, thus carrying a new
level of molecular regulation and thus safety. This project is to extend our work and build on
the success from a previous SMART award to further develop our prototype as well as derive
a more valuable platform technology to discover further product candidates. This will be
aimed at metastatic colorectal cancer, but later other solid cancers could be targeted.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| SHYDEN BIOTECHNOLOGY LTD | £164,903 | £ 98,941 |
Participant |
||
| ANASTASIS BIOTEC LIMITED |
People |
ORCID iD |
| Aga Epenetos (Project Manager) |